Reig Jofre launches sleep supplement in France

28 Jan 2018

Forté Pharma's new nutritional supplement combines natural extracts: valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

Forté Pharma, Reig Jofre’s nutritional supplements line, has launched Forté Nuit 8h in France, its home market. The new nutritional supplement extends the company's health range and represents the natural alternative to help to fight sleep disorders.

Reig Jofre launches sleep supplement in France

Forté Nuit 8h improves the latency time; it also provides quality rest for 8 hours, without drowsiness or side effects upon awakening and without causing dependence.

Forté Nuit 8h acts with a double effect thanks to its natural formula, the optimal dose of its ingredients and its original bilayer tablets format, which provides an immediate effect through the rapid melatonin release that favors the first phase of the sleep cycle, as well as a long-acting effect thanks to the combination of natural extracts, valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

Forté Pharma is planning Forté Nuit 8h’s international expansion and will start its marketing in Belgium during the first quarter of 2018.

Regarding the Spanish market, Forté Pharma plans to continue the development of the weight control segment during the first half of the year and to boost the rest of the categories in the second half.

Forte Pharma's portfolio is organized into four segments: energy (35% of its total sales), slimming (30%), health (22%) and beauty (13%) as at the end of September 2017.

At present, the marketing of Forte Pharma products is conducted mostly in Europe through its own sales network. Forte Pharma’s home market - France - is still the first market of the brand, which accounted for 67% of sales.

Read More

Related tags

Market News

Related news

New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more 
Symbiosis secures FDA viral vector process approval

Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New horizontal flow wrapping machine for hermetic packages

New horizontal flow wrapping machine for hermetic packages

3 Oct 2018

Greater product protection thanks to reliable sealing technologies.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Niche CDMO confirms spray drying for highly potent drugs

Niche CDMO confirms spray drying for highly potent drugs

1 Oct 2018

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Read more 
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

1 Oct 2018

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Read more